摘要:
There is provided an isolated multimeric or heterodimeric cytokine receptor comprising: a first polypeptide, wherein the first polypeptide comprises an amino acid sequence having at least 90 percent sequence identity with residues 20-732 of SEQ ID NO:111 or an amino acid sequence having at least 90 percent sequence identity with residues 20-649 of SEQ ID NO:109; and a second polypeptide comprising residues 28-429 of SEQ IDNO:7; wherein the multimeric or heterodimeric cytokine receptor binds a ligand comprising residues 27-164 of SEQ ID NO:2.
摘要:
There is provided an isolated multimeric or heterodimeric cytokine receptor comprising: a first polypeptide, wherein the first polypeptide comprises an amino acid sequence having at least 90 percent sequence identity with residues 20-732 of SEQ ID NO:111 or an amino acid sequence having at least 90 percent sequence identity with residues 20-649 of SEQ ID NO:109; and a second polypeptide comprising residues 28-429 of SEQ IDNO:7; wherein the multimeric or heterodimeric cytokine receptor binds a ligand comprising residues 27-164 of SEQ ID NO:2.
摘要翻译:提供了分离的多聚体或异二聚体细胞因子受体,其包含:第一多肽,其中第一多肽包含与SEQ ID NO:111的残基20-732具有至少90%序列同一性的氨基酸序列或具有SEQ ID NO: 与SEQ ID NO:109的残基20-649的至少90%的序列同一性; 和包含SEQ ID NO:7的残基28-429的第二多肽; 其中所述多聚体或异二聚体细胞因子受体结合包含SEQ ID NO:2的残基27-164的配体。
摘要:
There is provided the use of a polypeptide for the manufacture of a medicament for up-regulating IL-13RA2 gene expression in a mammal, wherein the polypeptide comprises a sequence of amino acid residues that is at least 90% identical to the sequence of amino acid residues of a polypeptide selected from: (a) a polypeptide comprising the amino acid sequence from residues 38 (Val) to 152 (Leu) as shown in SEQ ID NO:2; (b) a polypeptide comprising the amino acid sequence from residues 27 (Leu) to 164 (Thr) as shown in SEQ ID NO:2; (c) a polypeptide comprising the amino acid sequence from residues 24 (Ser) to 164 (Thr) as shown in SEQ ID NO:2; and (d) a polypeptide comprising the amino acid sequence from residues 1 (Met) to 164 (Thr) as shown in SEQ ID NO:2.
摘要翻译:提供多肽用于制备用于在哺乳动物中上调IL-13RA2基因表达的药物的用途,其中所述多肽包含与氨基酸序列至少90%相同的氨基酸残基序列 选自以下的多肽的残基:(a)包含如SEQ ID NO:2所示的残基38(Val)至152(Leu)的氨基酸序列的多肽; (b)如SEQ ID NO:2所示的包含残基27(Leu)至164(Thr))的氨基酸序列的多肽; (c)包含如SEQ ID NO:2所示的残基24(Ser)至164(Thr)的氨基酸序列的多肽; 和(d)包含如SEQ ID NO:2所示的残基1(Met)至164(Thr)的氨基酸序列的多肽。
摘要:
There is provided an antibody or antibody fragment which specifically binds to a portion of SEQ ID NO:2, wherein said portion consists of between 30 and 100 contiguous amino acids of SEQ ID NO:2, and wherein said portion contains amino acids selected from the group consisting of: (a) amino acid residues 54 to 59 of SEQ ID NO: 2; (b) amino acid residues 129 to 134 of SEQ ID NO: 2; (c) amino acid residues 53 to 58 of SEQ ID NO: 2; (d) amino acid residues 35 to 40 of SEQ ID NO: 2; (e) amino acid residues 33 to 38 of SEQ ID NO: 2; (f) amino acid residues 114 to 119 of SEQ ID NO: 2; (g) amino acid residues 101 to 105 of SEQ ID NO: 2; (h) amino acid residues 126 to 131 of SEQ ID NO: 2; (i) amino acid residues 113 to 118 of SEQ ID NO: 2; and (j) amino acid residues 158 to 162 of SEQ ID NO:2.
摘要翻译:提供了与SEQ ID NO:2的一部分特异性结合的抗体或抗体片段,其中所述部分由SEQ ID NO:2的30-100个连续氨基酸组成,并且其中所述部分含有选自 组成:(a)SEQ ID NO:2的氨基酸残基54至59; (b)SEQ ID NO:2的氨基酸残基129至134; (c)SEQ ID NO:2的氨基酸残基53至58; (d)SEQ ID NO:2的氨基酸残基35至40; (e)SEQ ID NO:2的氨基酸残基33至38; (f)SEQ ID NO:2的氨基酸残基114至119; (g)SEQ ID NO:2的氨基酸残基101至105; (h)SEQ ID NO:2的氨基酸残基126至131; (i)SEQ ID NO:2的氨基酸残基113至118; 和(j)SEQ ID NO:2的氨基酸残基158至162。
摘要:
There is provided an antibody or antibody fragment that specifically binds to a multimeric or heterodimeric cytokine receptor, wherein the multimeric or heterodimeric cytokine receptor comprises: a first polypeptide consisting of amino acid residues 20-732 of SEQ ID NO:111; and a second polypeptide consisting of amino acid residues 28-429, amino acid residues 28-739 or amino acid residues 28-979 of SEQ ID NO:7.
摘要翻译:提供了特异性结合多聚体或异二聚体细胞因子受体的抗体或抗体片段,其中多聚体或异二聚体细胞因子受体包含:由SEQ ID NO:111的氨基酸残基20-732组成的第一多肽; 和由SEQ ID NO:7的氨基酸残基28-429,氨基酸残基28-739或氨基酸残基28-979组成的第二多肽。